Literature DB >> 26414969

Spironolactone for resistant hypertension--hard to resist?

Hillel Sternlicht1, George L Bakris2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26414969     DOI: 10.1016/S0140-6736(15)00264-0

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  5 in total

1.  European guidelines on lifestyle changes for management of hypertension : Awareness and implementation of recommendations among German and European physicians.

Authors:  J Bolbrinker; L Zaidi Touis; H Gohlke; B Weisser; R Kreutz
Journal:  Herz       Date:  2017-05-22       Impact factor: 1.443

Review 2.  Drug Development for Hypertension: Do We Need Another Antihypertensive Agent for Resistant Hypertension?

Authors:  Eduardo Pimenta; David A Calhoun
Journal:  Curr Hypertens Rep       Date:  2016-04       Impact factor: 5.369

3.  Clinical characteristics, target organ damage and associate risk factors of resistant hypertension determined by ambulatory blood pressure monitoring in patients aged ≥ 80 years.

Authors:  Zhi-Ru Liang; Ling-Gen Gao; Jian Cao; Hua Cui; Li Fan; De-Wei Gao
Journal:  J Geriatr Cardiol       Date:  2017-05       Impact factor: 3.327

4.  Low Dose Spironolactone Monotherapy in the Management of Stage I Essential Hypertension: A Pilot Randomized, Double-Blind, Placebo-Controlled Trial.

Authors:  Armin Attar; Amir-Abbas Sadeghi; Fatemeh Amirmoezi; Kamran Aghasadeghi
Journal:  Acta Cardiol Sin       Date:  2018-01       Impact factor: 2.672

5.  Antisense Inhibition of Angiotensinogen With IONIS-AGT-LRx: Results of Phase 1 and Phase 2 Studies.

Authors:  Erin S Morgan; Yvonne Tami; Kuolung Hu; Michela Brambatti; Adam E Mullick; Richard S Geary; George L Bakris; Sotirios Tsimikas
Journal:  JACC Basic Transl Sci       Date:  2021-05-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.